In 2013, Prof. Jeong Han Kim of Konkuk University (KU) School of Medicine (Dept. of Digestive Organ Internal Medicine, KU Medical Center) published four articles on the treatment of chronic hepatitis B and liver cancer in SCI(E) and SCOPUS journals.
In particular, Prof. Kim introduced two articles on chronic hepatitis B (CHB) treatment in Clinical and Molecular Hepatology as the corresponding author. One was titled "Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients."
The other article, introduced in the same journal, was titled "HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data," revealed that long-term therapy showed positive effects as compared with short-term therapy.
Prof. Kim also published the "Value of the APASL severity score in patients with acute variceal bleeding: a single center experience" as the corresponding author in Hepatology International, an SCI(E) journal. The study covered salvage therapy for chronic hepatitis B patients with acute variceal bleeding and unsuccessful nucleoside analogue treatment outcomes.
Lastly, Prof. Kim's article "Predictive value of Refit Model for End-Stage Liver Disease, Refit Model for End-Stage Liver Disease-Na, and pre-existing scoring system for 3-month mortality in Korean patients with cirrhosis" was published in the Journal of Gastroenterology and Hepatology.
Posted by Eun Jin Cho